VoxCell BioInnovation sells a 3D-printed, fully vascularized human cancer tissue model designed to address high failure rates in oncology drug development. The company's hardware, software, and bioinks aim to let pharmaceutical researchers see if a drug candidate will work, or fail, before it reaches a human.
Founded in 2020, the Victoria-based company has moved from academic concept to a commercial tool with its first product launch and two key partnerships. The company's seed round was led by Canadian investor E-Fund. In 2024, VoxCell launched its Universal Bioink Kit [Techcouver.com, 2026]. In 2026, it announced collaborations with contract research organization Altasciences and biotech accelerator adMare BioInnovations [altasciences.com, 2026] [drug-dev.com, 2026].
The Vascular Wedge
Standard bioprinting output is often a static cluster of cells lacking the blood vessels, or vasculature, that tumors use to grow and spread. VoxCell's platform includes a bioprinter, vascularization software, proprietary bioinks, and ready-to-use tissue models. The vascular network is meant to mimic the physiological environment of a real tumor, allowing for more predictive testing of drug efficacy and toxicity.
Commercial Traction and Key Hires
VoxCell's commercial strategy blends product sales with embedded partnerships:
- The adMare partnership. The company is working with adMare BioInnovations to validate a novel antibody-based immune-modulating therapy using VoxCell's tissue models [drug-dev.com, 2026].
- The Altasciences integration. The deal with contract research organization Altasciences aims to embed VoxCell's 3D bioprinted tissue platforms into the CRO's discovery and preclinical services [altasciences.com, 2026].
To steer this commercial push, VoxCell appointed Graham Craig as Chief Commercial Officer in 2024 [ddw-online.com, 2026]. The company has also posted roles for a Tissue Engineer/Scientist and a Lead Mechatronics Engineer.
The Founder's Path from PhD to CEO
Dr. Karolina Valente, VoxCell's founder, CEO, and Chief Scientific Officer, built the company from her doctoral work. She completed her PhD in Mechanical Engineering at the University of Victoria in 2020, the same year she founded VoxCell [uvic.ca, 2026].
| Role | Name | Background Note |
|---|---|---|
| Founder, CEO & CSO | Dr. Karolina Valente | PhD in Mechanical Engineering, University of Victoria (2020) [uvic.ca, 2026] |
| Chief Commercial Officer | Graham Craig | Appointed 2024; leads global biz dev & partnerships [ddw-online.com, 2026] |
| Director of Engineering | Sebastian Steiner | Engineering leadership [LinkedIn, 2026] |
| Director, Biz Dev & Alliances | Kevin Vos, Ph.D. | Strategic partnerships [LinkedIn, 2026] |
Navigating a Crowded and Capital-Intensive Field
VoxCell operates in a capital-intensive sector with competitors including Aspect Biosystems, BICO, Allevi, and Axolotl Biosciences. The competitive pressure centers on proving that vascularization delivers a decisive improvement in predictive power. VoxCell's partnerships are early validation points, but the ultimate test is whether its data can convince large pharma to change entrenched preclinical workflows.
The Next Twelve Months
For a seed-stage biotech, the immediate future is about proof and capital. VoxCell will need to convert its partnerships with adMare and Altasciences into published case studies and repeat business. The company's seed backing from E-Fund provides runway, but the next round will likely need to be larger to fund the clinical validation and commercial scaling required to stand out in this field.